

Josef S Smolen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4455901/publications.pdf>

Version: 2024-02-01

447
papers

73,740
citations

1799

103
h-index

593

261
g-index

454
all docs

454
docs citations

454
times ranked

36466
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: â€˜Correspondence on â€˜Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Charles. Annals of the Rheumatic Diseases, 2023, 82, e110-e110.	0.9	1
2	Response to: â€˜Correspondence on â€˜Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementâ€™â€™ by Bandy<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e105-e105.	0.9	9
3	Response to: Where are the women â€˜Heroes and Pillars of Rheumatologyâ€™?. Annals of the Rheumatic Diseases, 2023, 82, e200-e200.	0.9	2
4	Response to: â€˜Comment on â€˜Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumabâ€™â€™ by Pethoe-Schramm<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e137-e137.	0.9	0
5	Response to: â€˜Correspondence on â€˜EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateâ€™â€™ by Fallon<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e174-e174.	0.9	14
6	Response to: â€˜Comment on: â€˜EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateâ€™â€™ by Gossec<i>et al</i>â€™â€™ by Wei<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e139-e139.	0.9	30
7	Response to: â€˜Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritisâ€™â€™ by Bugatti<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e56-e56.	0.9	1
8	Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables. Annals of the Rheumatic Diseases, 2022, 81, 175-183.	0.9	6
9	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Annals of the Rheumatic Diseases, 2022, 81, 335-343.	0.9	71
10	Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. Rheumatology, 2022, 61, 2815-2825.	1.9	12
11	Greetings from the editor 2022. Annals of the Rheumatic Diseases, 2022, 81, 1-3.	0.9	5
12	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 687-694.	0.9	43
13	Implementing a <sc>Treatâ€toâ€Target</sc> Approach for Rheumatoid Arthritis During the <sc>COVID</sc>â€19 Pandemic: Results of a Virtual Learning Collaborative Program. Arthritis Care and Research, 2022, 74, 572-578.	3.4	1
14	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Annals of the Rheumatic Diseases, 2022, 81, 823-830.	0.9	18
15	Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 622-631.	0.9	4
16	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the Rheumatic Diseases, 2022, 81, 1628-1639.	0.9	89
17	Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 838-844.	0.9	41
18	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. Journal of Rheumatology, 2022, 49, 694-699.	2.0	4

#	ARTICLE	IF	CITATIONS
19	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 937-943.	0.9	14
20	Reflections on a contemporary European tragedy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 747-748.	0.9	2
21	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	3.8	4
22	P196 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2022, 61, .	1.9	1
23	Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 748-750.	0.9	2
24	Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1374-1378.	0.9	6
25	Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss. <i>Bone and Joint Research</i> , 2022, 11, 484-493.	3.6	3
26	Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	3.4	12
27	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
28	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	1.9	14
29	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 242-249.	0.9	6
30	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. <i>Rheumatology</i> , 2021, 60, 2256-2266.	1.9	12
31	Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110225.	2.7	8
32	Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 884-890.	0.9	28
33	Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 83-84.	27.0	3
34	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
35	What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299.	1.9	4
36	O09 Safety profile of baricitinib for the treatment of RA up to 8.4 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2021, 60, .	1.9	1

#	ARTICLE	IF	CITATIONS
37	Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 677-678.	0.9	2
38	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	3.8	12
39	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	3.4	7
40	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1419-1428.	0.9	17
41	SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1345-1350.	0.9	211
42	Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. <i>Arthritis Research and Therapy</i> , 2021, 23, 220.	3.5	2
43	Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. <i>BMJ Open</i> , 2021, 11, e049850.	1.9	0
44	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	3.4	8
45	Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1519-1534.	2.3	42
46	Greetings from the editor 2021. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1-3.	0.9	13
47	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
48	Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e002038.	3.8	3
49	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020, 30, 36-43.	1.8	44
50	I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 360-368.	3.4	33
51	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 276-284.	3.4	25
52	Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 245-251.	3.4	20
53	Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 153-164.	1.9	21
54	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.4	39

#	ARTICLE	IF	CITATIONS
55	Treatmentâ€”Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care and Research, 2020, 72, 814-821.	3.4	6
56	Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. Journal of Autoimmunity, 2020, 108, 102379.	6.5	31
57	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Annals of the Rheumatic Diseases, 2020, 79, 123-131.	0.9	206
58	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. Rheumatology, 2020, 59, 1842-1852.	1.9	13
59	P276â€”Comparative effects of ixekizumab (IXE) vs adalimumab (ADA) across PsA patients defined by baseline characteristics: week 24 outcomes from SPIRIT-H2H. Rheumatology, 2020, 59, .	1.9	0
60	microRNAâ€”146a controls ageâ€”related bone loss. Aging Cell, 2020, 19, e13244.	6.7	20
61	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Science and Medicine, 2020, 7, e000424.	2.7	35
62	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Annals of the Rheumatic Diseases, 2020, 79, 1310-1319.	0.9	56
63	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open, 2020, 6, e001374.	3.8	36
64	Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. Rheumatology and Therapy, 2020, 7, 1021-1035.	2.3	21
65	Hand X-ray examination in two planes is not required for radiographic assessment of hand osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093493.	2.7	1
66	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1290-1297.	0.9	61
67	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 188.	3.5	2
68	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
69	O4â€”Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus. , 2020, , .		0
70	O8â€”Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
71	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Annals of the Rheumatic Diseases, 2020, 79, 1423-1431.	0.9	11
72	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 115.	3.5	11

#	ARTICLE	IF	CITATIONS
73	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786.	0.9	104
74	Greetings from the editor 2020. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1-2.	0.9	18
75	Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 874-882.	0.9	16
76	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.9	609
77	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001095.	3.8	48
78	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 709-718.	3.4	22
79	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 643-644.	3.4	6
80	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204
81	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096.	3.8	3
82	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.9	205
83	Insights into the treatment of rheumatoid arthritis: A paradigm in medicine. <i>Journal of Autoimmunity</i> , 2020, 110, 102425.	6.5	27
84	2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.9	463
85	Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093348.	2.7	1
86	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759.	0.9	167
87	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452.	0.9	42
88	Environmental arginine controls multinuclear giant cell metabolism and formation. <i>Nature Communications</i> , 2020, 11, 431.	12.8	37
89	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
90	Rheumatoid arthritis Primer – behind the scenes. <i>Nature Reviews Disease Primers</i> , 2020, 6, 32.	30.5	20

#	ARTICLE	IF	CITATIONS
91	Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. Arthritis and Rheumatology, 2020, 72, 1227-1229.	5.6	1
92	Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. Nature Medicine, 2020, 26, 974-980.	30.7	9
93	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. Joint Bone Spine, 2020, 87, 449-454.	1.6	14
94	Greetings from the editor. Annals of the Rheumatic Diseases, 2020, 79, 677-678.	0.9	30
95	O24â€œConcomitant treatment with MTX does not increase the efficacy of ustekinumab or TFNi in PsA: results from the PsABio study. Rheumatology, 2020, 59, .	1.9	0
96	2018 update of the EULAR recommendations for the management of hand osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 16-24.	0.9	273
97	To DAPSA or not to DAPSA? That is not the question. Annals of the Rheumatic Diseases, 2019, 78, e61-e61.	0.9	3
98	Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nature Reviews Rheumatology, 2019, 15, 633-634.	8.0	45
99	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759
100	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
101	IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes. Experimental and Molecular Medicine, 2019, 51, 1-11.	7.7	49
102	Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns. PLoS ONE, 2019, 14, e0219698.	2.5	12
103	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. Rheumatic Disease Clinics of North America, 2019, 45, 315-324.	1.9	1
104	MicroRNA-155 Controls T Helper Cell Activation During Viral Infection. Frontiers in Immunology, 2019, 10, 1367.	4.8	24
105	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 164.	3.5	24
106	Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Research and Therapy, 2019, 21, 231.	3.5	6
107	Treat to Target in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, 477-485.	1.9	31
108	074â€œSummary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis. Rheumatology, 2019, 58, .	1.9	1

#	ARTICLE	IF	CITATIONS
109	245â€fRemission/low disease activity is an achievable treatment target in psoriatic arthritis (PsA): results from a routine care European cohort of PsA patients treated with ustekinumab or TNF inhibitors. Rheumatology, 2019, 58, .	1.9	2
110	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 634-640.	0.9	51
111	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. Journal of Rheumatology, 2019, 46, 1159-1163.	2.0	11
112	FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes. Laboratory Investigation, 2019, 99, 648-658.	3.7	20
113	Achieving Clinical Remission for Patients With Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2019, 321, 457.	7.4	17
114	Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open, 2019, 5, e000900.	3.8	67
115	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. Rheumatology and Therapy, 2019, 6, 409-419.	2.3	18
116	Greetings from the editor. Annals of the Rheumatic Diseases, 2019, 78, 715-715.	0.9	0
117	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet, The, 2019, 393, 2303-2311.	13.7	237
118	Multimodal [18F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNF± Transgenic Mice. Journal of Bone and Mineral Research, 2019, 34, 1632-1645.	2.8	8
119	Effects of a brief workplace-centered consultation for employees with musculoskeletal pain on health outcomes: a prospective cohort study. Scientific Reports, 2019, 9, 5867.	3.3	4
120	An intergenerational program based on psycho-motor activity promotes well-being and interaction between preschool children and older adults: results of a process and outcome evaluation study in Austria. BMC Public Health, 2019, 19, 254.	2.9	12
121	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.9	1,265
122	Risk profiling for a refractory course of rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2019, 49, 211-217.	3.4	62
123	THU0078â€...SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. , 2019, , .		5
124	THU0431â€...FREQUENCY OF TENDON INVOLVEMENT AND ITS EFFECT ON HAND FUNCTION IN HAND OSTEOARTHRITIS. , 2019, , .		0
125	185â€...Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial. , 2019, , .		4
126	AB1219â€...EFFECTS OF A WORKPLACE-CENTERED COUNSELING OF INDIVIDUALS WITH MUSCULOSKELETAL COMPLAINTS: A PROSPECTIVE COHORT STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
127	FRI0193â€¦2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
128	THU0101â€¦TORQUE TENO VIRAL LOAD FOR MONITORING OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS. , 2019, , .		0
129	OP0229PHASEâ€¦II CLINICAL TRIALS SYSTEMATICALLY OVERESTIMATE TREATMENT EFFECTS OF SUBSEQUENT PHASE III TRIALS IN RHEUMATOID ARTHRITIS. , 2019, , .		0
130	OP0007â€¦HIGH BODY MASS INDEX (BMI) IN PSORIATIC ARTHRITIS (PSA) IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY IN JOINTS AND SKIN, IMPAIRED QUALITY OF LIFE AND MORE DISABILITY: RESULTS FROM THE PSABIO STUDY. , 2019, , .		3
131	THU0193â€¦EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (â‰¤2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY. , 2019, , .		3
132	SAT0061â€¦IMPORTANT ROLE OF CD11C+ CELLS IN INFLAMMATORY ARTHRITIS. , 2019, , .		0
133	SAT0162â€¦A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
134	LB0005â€¦MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: 24-WEEK RESULTS. , 2019, , .		0
135	FRI0164â€¦INCIDENCE RATE AND CHARACTERIZATION OF HERPES ZOSTER IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: AN UPDATE FROM BARICITINIB CLINICAL STUDIES. , 2019, , .		1
136	THU0133â€¦TENDERNESS CAN BE REGARDED AS A SIGN OF INFLAMMATION IN RHEUMATOID ARTHRITIS. , 2019, , .		0
137	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open, 2019, 5, e001040.	3.8	28
138	Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1609-1615.	0.9	33
139	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. Journal of Rheumatology, 2019, 46, 7-18.	2.0	207
140	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Annals of the Rheumatic Diseases, 2019, 78, 171-178.	0.9	66
141	Greetings from the editor 2019. Annals of the Rheumatic Diseases, 2019, 78, 1-2.	0.9	18
142	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. Journal of Rheumatology, 2019, 46, 721-726.	2.0	45
143	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Annals of the Rheumatic Diseases, 2019, 78, 201-208.	0.9	59
144	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36

#	ARTICLE	IF	CITATIONS
145	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD Open, 2018, 4, e000564.	3.8	29
146	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213030.	0.9	183
147	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology, 2018, 57, 900-908.	1.9	47
148	Rheumatoid arthritis. Nature Reviews Disease Primers, 2018, 4, 18001.	30.5	1,441
149	Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase 2 Clinical Trial. Arthritis Care and Research, 2018, 70, 1551-1556.	3.4	11
150	Targeted inhibition of Janus kinases abates interferon gamma-induced invasive behaviour of fibroblast-like synoviocytes. Rheumatology, 2018, 57, 572-577.	1.9	32
151	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. Annals of the Rheumatic Diseases, 2018, 77, 782-783.	0.9	18
152	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis Care and Research, 2018, 70, 428-438.	3.4	129
153	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.9	484
154	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Arthritis Care and Research, 2018, 70, 571-581.	3.4	91
155	Contribution of Genetic Factors to Lower DHEAS in Patients with Rheumatoid Arthritis. Cellular and Molecular Neurobiology, 2018, 38, 379-383.	3.3	4
156	Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Annals of the Rheumatic Diseases, 2018, 77, 234-240.	0.9	107
157	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Annals of the Rheumatic Diseases, 2018, 77, 165-174.	0.9	173
158	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 345-355.	5.6	72
159	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 289-292.	0.9	22
160	Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management. Annals of the Rheumatic Diseases, 2018, 77, 18-20.	0.9	31
161	Targeting IL-6: A review of data. Considerations in Medicine, 2018, 2, 12-18.	0.0	3
162	Response to: "The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies" by Tillett et al. Annals of the Rheumatic Diseases, 2018, 77, e24-e24.	0.9	1

#	ARTICLE	IF	CITATIONS
163	Considering new lessons about the use of IL-6 inhibitors in arthritis. Considerations in Medicine, 2018, 2, 7-11.	0.0	4
164	Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate-inadequate responder patient population. Rheumatology, 2018, 57, .	1.9	0
165	Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. Rheumatology, 2018, 57, .	1.9	0
166	Functional consultation and exercises improve grip strength in osteoarthritis of the hand – a randomised controlled trial. Arthritis Research and Therapy, 2018, 20, 253.	3.5	22
167	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD Open, 2018, 4, e000773.	3.8	9
168	Diagnosis and Management of Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2018, 320, 1360.	7.4	1,257
169	Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2018, 77, 1757-1764.	0.9	113
170	Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved disease activity index for psoriatic arthritis remission. Rheumatology, 2018, 57, .	1.9	0
171	Disease activity assessment in patients with psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 401-414.	3.3	17
172	Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. Rheumatology, 2018, 57, 1933-1937.	1.9	26
173	Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	3
174	Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities. Rheumatology, 2018, 57, .	1.9	1
175	Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis: two year results from the FUTURE 2 study. Rheumatology, 2018, 57, .	1.9	0
176	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Rheumatology and Therapy, 2018, 5, 341-353.	2.3	9
177	mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation. Cell Reports, 2018, 23, 2157-2167.	6.4	62
178	Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. Vaccine, 2018, 36, 4875-4879.	3.8	37
179	Non-classical monocytes as mediators of tissue destruction in arthritis. Annals of the Rheumatic Diseases, 2018, 77, 1490-1497.	0.9	65
180	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. RMD Open, 2018, 4, e000602.	3.8	13

#	ARTICLE	IF	CITATIONS
181	Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1566-1572.	0.9	23
182	Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 876.	4.8	49
183	Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 8.	3.5	29
184	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	3.5	18
185	CCR6 controls autoimmune but not innate immunity-driven experimental arthritis. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5278-5285.	3.6	10
186	The eumusc.net standards of care for rheumatoid arthritis: importance and current implementation according to patients and healthcare providers in the Netherlands. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 275-283.	0.8	1
187	Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 362-370.	0.8	3
188	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 58-64.	0.9	146
189	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
190	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, kew390.	1.9	36
191	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.9	393
192	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1113-1136.	0.9	195
193	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.9	111
194	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
195	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 855-861.	0.9	61
196	Response to: "2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?" by Misra et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e48-e48.	0.9	4
197	Response to: "The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis" by PiriÅ et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e50-e50.	0.9	0
198	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734.	5.6	39

#	ARTICLE	IF	CITATIONS
199	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet</i> , 2017, 390, 457-468.	13.7	360
200	Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1374-1380.	5.6	40
201	MicroRNA-146a governs fibroblast activation and joint pathology in arthritis. <i>Journal of Autoimmunity</i> , 2017, 82, 74-84.	6.5	43
202	A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 831-839.	0.9	124
203	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1102-1107.	0.9	131
204	Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 193-198.	3.4	14
205	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1101-1136.	0.9	277
206	04.05â€¦The metabolic checkpoint kinase mtor regulates the rheumatoid mesenchymal tissue response to inflammation. , 2017, , .		0
207	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017, 3, e000445.	3.8	5
208	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779.	1.9	49
209	08.28â€¦The prognostic value of iga autoantibodies (rheumatoid factor and acpa) for prediction of the therapeutic response to anti-tnf therapy in patients with rheumatoid arthritis. , 2017, , .		0
210	The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2038-2045.	0.9	38
211	The new editor greets you. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1636-1636.	0.9	4
212	01.11â€¦Resident non-classical monocytes are critically important for tissue destruction in arthritis. , 2017, , .		0
213	04.13â€¦The transcription factor foxo3 differentially regulates the expression of proinflammatory genes in rheumatoid fibroblast-like synoviocytes. , 2017, , .		0
214	Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000546.	3.8	39
215	A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1598-1602.	0.9	54
216	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727.	5.6	24

#	ARTICLE	IF	CITATIONS
217	Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. <i>Advances in Therapy</i> , 2017, 34, 91-108.	2.9	43
218	04.15â€¦Resolution of systemic inflammatory processes and regeneration of inflammation-driven bone damage upon tn timerk blockade as monitored by in vivo multimodal pet-ct imaging in tn timerk driven experimental arthritis. , 2017, , .		0
219	04.07â€¦Microrna-146a controls local bone destruction by regulating fibroblast induced osteoclastogenesis in inflammatory arthritis. , 2017, , .		0
220	MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus. <i>PLoS ONE</i> , 2017, 12, e0181015.	2.5	30
221	Opportunities and challenges in rheumatology research in Central Europe. <i>Arthritis Research and Therapy</i> , 2017, 19, 196.	3.5	3
222	02.06â€¦Ccr6 modulates severity of arthritis in T cell dependent manner. , 2017, , .		1
223	Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. , 2017, 34, 91.		1
224	A Combination of CD28 (rs1980422) and IRF5 (rs10488631) Polymorphisms Is Associated with Seropositivity in Rheumatoid Arthritis: A Case Control Study. <i>PLoS ONE</i> , 2016, 11, e0153316.	2.5	20
225	Treat-to-target as an approach in inflammatory arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 297-302.	4.3	45
226	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
227	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271.	0.9	26
228	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016, 2, e000221.	3.8	38
229	Advances in targeted therapy. <i>Rheumatology</i> , 2016, 55, ii1-ii2.	1.9	0
230	Preservation of cartilage and bone architecture is the most important aspect for maintaining functionality in longstanding experimental arthritis. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1329-1338.	2.4	39
231	Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study. <i>BMJ Open</i> , 2016, 6, e010555.	1.9	32
232	Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1024-1026.	2.0	6
233	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	27.0	499
234	Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 81-87.	3.4	18

#	ARTICLE	IF	CITATIONS
235	Rheumatoid arthritis. Lancet, The, 2016, 388, 2023-2038.	13.7	2,989
236	Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. Journal of Experimental Medicine, 2016, 213, 1937-1950.	8.5	75
237	Efficacy and Safety of ABTâ€494, a Selective JAKâ€1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2016, 68, 2857-2866.	5.6	172
238	Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Rheumatology, 2016, 55, 1458-1465.	1.9	15
239	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet, The, 2016, 388, 2763-2774.	13.7	144
240	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nature Reviews Rheumatology, 2016, 12, 743-750.	8.0	71
241	Safety and efficacy of biosimilars in oncology. Lancet Oncology, The, 2016, 17, e502-e509.	10.7	58
242	Response to: â€Evidence for treating rheumatoid arthritis to target: results of a systematic literature search updateâ€™ by Goswami<i>et al</i>. Annals of the Rheumatic Diseases, 2016, 75, e36-e36.	0.9	2
243	Title is missing!. Japanese Journal of Clinical Immunology, 2016, 39, 388a-388a.	0.0	0
244	Nicotinic acetylcholine receptors modulate osteoclastogenesis. Arthritis Research and Therapy, 2016, 18, 63.	3.5	32
245	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases, 2016, 75, 16-22.	0.9	275
246	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.9	1,114
247	Relation of Nailfold Capillaries and Autoantibodies to Mortality in Patients With Raynaud Phenomenon. Circulation, 2016, 133, 509-517.	1.6	18
248	Initial evidence for the link between activities and health: Associations between a balance of activities, functioning and serum levels of cytokines and C-reactive protein. Psychoneuroendocrinology, 2016, 65, 138-148.	2.7	12
249	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 490-498.	0.9	98
250	Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. Rheumatology, 2016, 55, 710-720.	1.9	47
251	Patient global assessment in psoriatic arthritis â€“ what does it mean? An analysis of 223Âpatients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine, 2016, 83, 335-340.	1.6	35
252	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. Journal of Rheumatology, 2016, 43, 203-207.	2.0	20

#	ARTICLE	IF	CITATIONS
253	Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 811-818.	0.9	325
254	Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1479-1485.	0.9	63
255	Information technology concerning SDAI and CDAI. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S45-S48.	0.8	7
256	Information technology in rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1.	0.8	24
257	Response to “Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis”™. <i>Arthritis Research and Therapy</i> , 2015, 17, 166.	3.5	1
258	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naïve patients with Early Erosive rheumatoid arthritis (AGREE). <i>Arthritis Research and Therapy</i> , 2015, 17, 157.	3.5	37
259	Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 133.	3.5	17
260	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 203.	3.5	23
261	Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 229.	3.5	73
262	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015, 54, 994-1007.	1.9	51
263	Do patient-reported outcome measures cover personal factors important to people with rheumatoid arthritis? A mixed methods design using the International Classification of Functioning, Disability and Health as frame of reference. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 27.	2.4	17
264	Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study. <i>Journal of Rheumatology</i> , 2015, 42, 1099-1104.	2.0	39
265	The patient perspective on remission in rheumatoid arthritis: “You've got limits, but you're back to being you again”™. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1004-1010.	0.9	71
266	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2015, 54, 2076-2084.	1.9	74
267	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 532-537.	0.9	10
268	Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 227-233.	0.9	41
269	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289.	8.0	372
270	CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 6.	3.5	19

#	ARTICLE	IF	CITATIONS
271	Biosimilar safety factors in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S9-S15.	3.4	39
272	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173.	3.4	58
273	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1567-1570.	0.9	31
274	Definitions of occupational balance and their coverage by instruments. <i>British Journal of Occupational Therapy</i> , 2015, 78, 4-15.	0.9	28
275	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor γ inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	3.5	49
276	Regulatory T cell-deficient scurfy mice develop systemic autoimmune features resembling lupus-like disease. <i>Arthritis Research and Therapy</i> , 2015, 17, 35.	3.5	68
277	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.9	36
278	Clocking in: chronobiology in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 349-356.	8.0	91
279	Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 230.	3.5	24
280	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	1.9	23
281	Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e67-e67.	0.9	12
282	Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1145-1149.	0.9	68
283	Novel therapies in rheumatoid arthritis: small molecules. , 2015, , 251-266.		0
284	Treatment of psoriatic arthritis: management recommendations. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S73-7.	0.8	20
285	Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S48-50.	0.8	30
286	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1811-1818.	0.9	29
287	Interphalangeal Osteoarthritis Radiographic Simplified (iOARS) score: a radiographic method to detect osteoarthritis of the interphalangeal finger joints based on its histopathological alterations. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1983-1989.	0.9	4
288	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) Tj ETQq0 0 0 rgBT /Overlock 10 Tf therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1616-1625.	0.9	135

#	ARTICLE	IF	CITATIONS
289	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1755-1760.	0.9	11
290	Health determining concepts important to people with Crohn's disease and their coverage by patient-reported outcomes of health and wellbeing. Journal of Crohn's and Colitis, 2014, 8, 45-55.	1.3	37
291	Proposal for a new nomenclature of disease-modifying antirheumatic drugs: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 3-5.	0.9	212
292	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.9	558
293	Mechanisms of tissue damage in arthritis. Seminars in Immunopathology, 2014, 36, 531-540.	6.1	43
294	Multimorbidity and rheumatic conditionsâ€”enhancing the concept of comorbidity. Nature Reviews Rheumatology, 2014, 10, 252-256.	8.0	103
295	Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects. Rheumatology, 2014, 53, 2136-2142.	1.9	25
296	Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Annals of the Rheumatic Diseases, 2014, 73, 902-905.	0.9	82
297	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Research and Therapy, 2014, 16, R56.	3.5	108
298	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases, 2014, 73, 492-509.	0.9	1,688
299	Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Annals of the Rheumatic Diseases, 2014, 73, 114-123.	0.9	118
300	Development of a new occupational balance-questionnaire: incorporating the perspectives of patients and healthy people in the design of a self-reported occupational balance outcome instrument. Health and Quality of Life Outcomes, 2014, 12, 45.	2.4	45
301	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2014, 73, 6-16.	0.9	397
302	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet, The, 2014, 383, 321-332.	13.7	232
303	A1.81â€…Mincle is not essential in T-cell independent arthritis models. Annals of the Rheumatic Diseases, 2014, 73, A35.3-A36.	0.9	0
304	A8.30â€…Analysis of monocyte-fibroblast interaction in 3D synovial micromass tissue cultures. Annals of the Rheumatic Diseases, 2014, 73, A88.1-A88.	0.9	0
305	A1.82â€…Limited role of microrna 155 innate immunity dependent arthritis. Annals of the Rheumatic Diseases, 2014, 73, A36.1-A36.	0.9	1
306	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet, The, 2013, 381, 918-929.	13.7	311

#	ARTICLE	IF	CITATIONS
307	Sonographic Joint Assessment in Rheumatoid Arthritis: Associations With Clinical Joint Assessment During a State of Remission. <i>Arthritis and Rheumatism</i> , 2013, 65, 2005-2014.	6.7	56
308	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 804-814.	0.9	504
309	Tumor necrosis factor- α -inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor- α -driven model of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 608-617.	6.7	44
310	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	2.0	108
311	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 583-589.	0.9	80
312	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 64-71.	0.9	183
313	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.9	102
314	Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1335-1341.	0.9	36
315	Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1156-1162.	0.9	56
316	Forget personalised medicine and focus on abating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 3-6.	0.9	98
317	Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 241-244.	0.9	44
318	Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 7-12.	0.9	24
319	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.9	114
320	Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 875-880.	0.9	69
321	A8.7-Functional Impairment in an Animal Model for Rheumatoid Arthritis Assessed as Changes in Gait is Due to Joint Destruction But Not Synovial Inflammation Per Se. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A59.2-A60.	0.9	0
322	A2.19-The Role of microRNA 155 in Innate Immunity and Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A11.2-A11.	0.9	0
323	A9.7-Loss of PTEN in Myeloid Cells Controls Inflammatory Bone Destruction by Regulating the Osteoclastogenic Potential of Myeloid Cells. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A66.3-A67.	0.9	0
324	A4.6-Effects of Cholic Acid and its Derivatives in Experimental Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A25.2-A26.	0.9	0

#	ARTICLE	IF	CITATIONS
325	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1671-1679.	0.9	53
326	Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 687-693.	0.9	119
327	Real time in vivo analysis of granulomonocytic cell migration in the collagen induced arthritis model. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A73.2-A73.	0.9	0
328	Muscle wasting in hTNF α mice, an animal model for rheumatoid arthritis, due to increased cathepsin L expression. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A45.1-A45.	0.9	0
329	Sustained PI3-kinase activity in myeloid cells enhances osteoclastogenesis and augments local bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A67.1-A67.	0.9	0
330	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1190-1196.	0.9	82
331	Developing an effective treatment algorithm for rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, v48-v54.	1.9	36
332	Inflammatory bone loss: pathogenesis and therapeutic intervention. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 234-250.	46.4	601
333	The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 235-243.	8.0	86
334	Therapeutic blockade of TNF in patients with SLE—Promising or crazy?. <i>Autoimmunity Reviews</i> , 2012, 11, 321-325.	5.8	102
335	Interferon signals and monocytic sensitization of the interferon γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 400-408.	6.7	31
336	Treat-to-target: rationale and strategies. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S2-6.	0.8	22
337	Infliximab: 12 years of experience. <i>Arthritis Research and Therapy</i> , 2011, 13, S2.	3.5	60
338	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.9	657
339	Monitoring rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 252-258.	4.3	32
340	Interleukin α 6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute α phase reactants. <i>Arthritis and Rheumatism</i> , 2011, 63, 43-52.	6.7	141
341	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
342	Essential role of microRNA α 155 in the pathogenesis of autoimmune arthritis in mice. <i>Arthritis and Rheumatism</i> , 2011, 63, 1281-1288.	6.7	240

#	ARTICLE	IF	CITATIONS
343	On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al. <i>Arthritis and Rheumatism</i> , 2011, 63, 3182-3185.	6.7	1
344	Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. <i>Arthritis and Rheumatism</i> , 2011, 63, 3702-3711.	6.7	122
345	Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 381-388.	1.9	109
346	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.9	394
347	Sensitisation of the IFN-Stat1-signalling-pathway in rheumatoid arthritis monocytes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A15-A16.	0.9	0
348	Nicotinic acetylcholine receptor activation completely blocks osteoclastogenesis by interfering with osteoclast precursor differentiation in vitro. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A74-A75.	0.9	1
349	Combined depletion of interleukin 1 and interleukin 6 does not exceed single depletion of interleukin 1 in TNF mediated arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A72-A72.	0.9	0
350	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1631-1640.	0.9	63
351	Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1975-1980.	0.9	54
352	Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 733-739.	0.9	159
353	Multi-targeted kinase inhibitor PKC412 diminishes osteoclastogenesis and counteracts osteoclast function in vitro. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A81-A81.	0.9	0
354	Reporting of long-term extension studies: lack of consistency calls for consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 886-890.	0.9	64
355	Micro-RNA 155 controls the pathogenesis of autoimmune arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A79-A80.	0.9	0
356	Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review. <i>Arthritis Care and Research</i> , 2010, 62, 108-117.	3.4	73
357	Rapid and sustained improvement in bone and cartilage turnover markers with the anti-IL-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. <i>Arthritis and Rheumatism</i> , 2010, 62, 33-43.	6.7	181
358	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
359	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 495-502.	0.9	136
360	Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1403-1406.	0.9	20

#	ARTICLE	IF	CITATIONS
361	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.9	203
362	Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 536-541.	0.9	117
363	How well can we compare different biologic agents for RA?. <i>Nature Reviews Rheumatology</i> , 2010, 6, 247-248.	8.0	8
364	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 575-578.	0.9	47
365	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.9	1,429
366	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1441-1447.	0.9	274
367	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1004-1009.	0.9	179
368	Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1058-1064.	0.9	95
369	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.9	2,994
370	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.9	1,711
371	The assessment of disease activity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S18-27.	0.8	24
372	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1114-1121.	1.9	198
373	Ten years of infliximab: Insights from clinical trials in rheumatoid arthritis. <i>European Journal of Pharmacology</i> , 2009, 623, S5-S9.	3.5	4
374	Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. <i>Arthritis and Rheumatism</i> , 2009, 60, 2747-2756.	6.7	237
375	Tocilizumab. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 273-274.	46.4	48
376	Developments in the clinical understanding of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, 204.	3.5	56
377	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor γ inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet</i> , The, 2009, 374, 210-221.	13.7	497
378	The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. <i>Arthritis Research and Therapy</i> , 2008, 10, 208.	3.5	69

#	ARTICLE	IF	CITATIONS
379	Cytokines as Therapeutic Targets: Advances and Limitations. <i>Immunity</i> , 2008, 28, 440-444.	14.3	69
380	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2008, 371, 987-997.	13.7	1,269
381	When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1497-1498.	0.9	28
382	I Have Mastered the Challenge of Living With a Chronic Disease: Life Stories of People With Rheumatoid Arthritis. <i>Qualitative Health Research</i> , 2008, 18, 658-669.	2.1	64
383	Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 296-297.	3.2	3
384	Activity assessments in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 306-313.	4.3	32
385	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007, 370, 1861-1874.	13.7	859
386	Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 79-88.	6.7	84
387	Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. <i>Arthritis and Rheumatism</i> , 2007, 57, 487-494.	6.7	82
388	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2007, 56, 3226-3235.	6.7	225
389	Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. <i>Arthritis and Rheumatism</i> , 2007, 57, 1287-1295.	6.7	61
390	Dickkopf-1 is a master regulator of joint remodeling. <i>Nature Medicine</i> , 2007, 13, 156-163.	30.7	1,161
391	The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 663-675.	3.3	134
392	Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1465-74.	2.0	34
393	What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials. <i>Journal of rheumatology Supplement, The</i> , 2007, 79, 15-20.	2.2	4
394	Expanding the frontiers of therapy. <i>Arthritis Research and Therapy</i> , 2006, 8, S1.	3.5	3
395	Interleukin-6: a new therapeutic target. <i>Arthritis Research and Therapy</i> , 2006, 8, S5.	3.5	101
396	Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. <i>Arthritis Research and Therapy</i> , 2006, 8, R46.	3.5	22

#	ARTICLE	IF	CITATIONS
397	The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2006, 32, 9-44.	1.9	124
398	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis and Rheumatism, 2006, 54, 702-710.	6.7	390
399	The American College of Rheumatology N (ACR-N) debate: Going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. Arthritis and Rheumatism, 2006, 54, 377-378.	6.7	13
400	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis and Rheumatism, 2006, 54, 2784-2792.	6.7	241
401	Measuring functioning in patients with hand osteoarthritis—content comparison of questionnaires based on the International Classification of Functioning, Disability and Health (ICF). Rheumatology, 2006, 45, 1534-1541.	1.9	66
402	Pro-Inflammatory Cytokines in Rheumatoid Arthritis: Pathogenetic and Therapeutic Aspects. Clinical Reviews in Allergy and Immunology, 2005, 28, 239-248.	6.5	67
403	Challenges of predicting treatment response in patients with rheumatoid arthritis. Nature Clinical Practice Rheumatology, 2005, 1, 62-63.	3.2	22
404	Therapeutic strategies in early rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2005, 19, 163-177.	3.3	74
405	Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis and Rheumatism, 2005, 52, 1227-1236.	6.7	583
406	Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis from the patient perspective: A qualitative study. Arthritis and Rheumatism, 2005, 53, 431-439.	6.7	88
407	Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis and Rheumatism, 2005, 52, 2625-2636.	6.7	428
408	Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?. Arthritis and Rheumatism, 2005, 52, 2975-2983.	6.7	77
409	The need for new classification criteria for rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 3333-3336.	6.7	46
410	Reply.. Arthritis and Rheumatism, 2005, 52, 4045-4047.	6.7	5
411	Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Research, 2005, 7, R796.	2.0	838
412	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis and Rheumatism, 2004, 50, 3432-3443.	6.7	1,080
413	Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis. American Journal of Pathology, 2004, 164, 543-555.	3.8	130
414	The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. Journal of rheumatology Supplement, The, 2004, 71, 13-20.	2.2	18

#	ARTICLE	IF	CITATIONS
415	The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care. <i>Current Rheumatology Reports</i> , 2003, 5, 336-340.	4.7	0
416	Therapeutic strategies for rheumatoid arthritis. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 473-488.	46.4	727
417	Objectives and strategies for rheumatoid arthritis therapy: yesterday vs. today. <i>Drugs of Today</i> , 2003, 39 Suppl B, 3-8.	1.1	1
418	Characterization of Autoreactive T Cells to the Autoantigens Heterogeneous Nuclear Ribonucleoprotein A2 (RA33) and Filaggrin in Patients with Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2002, 169, 1068-1076.	0.8	70
419	Therapy of systemic lupus erythematosus: a look into the future. <i>Arthritis Research</i> , 2002, 4, S25.	2.0	15
420	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002, 47, 215-218.	6.7	132
421	Criteria for early rheumatoid arthritis: From Bayes' law revisited to new thoughts on pathogenesis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1155-1159.	6.7	63
422	Osteoclasts are essential for TNF- α -mediated joint destruction. <i>Journal of Clinical Investigation</i> , 2002, 110, 1419-1427.	8.2	437
423	Osteoclasts are essential for TNF- α -mediated joint destruction. <i>Journal of Clinical Investigation</i> , 2002, 110, 1419-1427.	8.2	255
424	Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. <i>Journal of Rheumatology</i> , 2002, 29, 1631-8.	2.0	83
425	Alterations of dendritic cells in systemic lupus erythematosus: Phenotypic and functional deficiencies. <i>Arthritis and Rheumatism</i> , 2001, 44, 856-865.	6.7	98
426	Rheumatoid arthritis is more than cytokines: Autoimmunity and rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2218-2220.	6.7	28
427	Alterations of dendritic cells in systemic lupus erythematosus: Phenotypic and functional deficiencies. <i>Arthritis and Rheumatism</i> , 2001, 44, 856-865.	6.7	3
428	Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 2501-2512.	6.7	524
429	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602.	27.0	2,910
430	Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. <i>FASEB Journal</i> , 1999, 13, 833-842.	0.5	72
431	A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities: I. Precision, sensitivity, and specificity. <i>Arthritis and Rheumatism</i> , 1999, 42, 455-464.	6.7	163
432	Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. <i>Lancet</i> , The, 1999, 353, 259-266.	13.7	706

#	ARTICLE	IF	CITATIONS
433	Infliximab (chimeric anti-tumour necrosis factor $\hat{1}$ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. <i>Lancet</i> , The, 1999, 354, 1932-1939.	13.7	2,266
434	A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities: I. Precision, sensitivity, and specificity. , 1999, 42, 455.		1
435	Severe infections in plasmapheresis-treated systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998, 41, 414-420.	6.7	71
436	Mixed connective tissue disease: To be or not to be?. <i>Arthritis and Rheumatism</i> , 1998, 41, 768-777.	6.7	167
437	Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation. <i>Arthritis and Rheumatism</i> , 1998, 41, 1446-1455.	6.7	244
438	Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor γ monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1998, 41, 1552-1563.	6.7	1,560
439	The concurrence of rheumatoid arthritis and limited systemic sclerosis: Clinical and serologic characteristics of an overlap syndrome. <i>Arthritis and Rheumatism</i> , 1998, 41, 1938-1945.	6.7	56
440	Severe infections in plasmapheresisâ€treated systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998, 41, 414-420.	6.7	2
441	Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. <i>Arthritis and Rheumatism</i> , 1997, 40, 413-418.	6.7	56
442	Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins ? A link between RA, SLE and MCTD. <i>Molecular Biology Reports</i> , 1996, 23, 167-171.	2.3	28
443	Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. <i>Arthritis and Rheumatism</i> , 1995, 38, 38-43.	6.7	226
444	Demonstration of a new antinuclear antibody (ANTI-RA33) that is highly specific for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1989, 32, 1515-1520.	6.7	113
445	Systemic Lupus Erythematosus: Delineation of Subpopulations by Clinical, Serologic, and T Cell Subset Analysis. <i>American Journal of the Medical Sciences</i> , 1985, 289, 139-147.	1.1	36
446	Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1982, 72, 783-790.	1.5	160
447	078â€Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study. <i>Rheumatology</i> , 0, , .	1.9	1